Sutent and Nexavar Put Brakes on Renal-Cell Carcinoma

Article

NEW YORK -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.

NEW YORK, Jan. 10 -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.

Sutent more than doubled progression-free survival (P

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Upadacitinib Shows Long-Term Efficacy in Adolescent Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock

Upadacitinib Shows Long-Term Efficacy in Adolescent Atopic Dermatitis: Daily Dose

Sydney Jennings
December 24th 2024
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose / image credit: ©New Africa/AdobeStock

New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose

Sydney Jennings
December 23rd 2024
Article

Your daily dose of the clinical news you may have missed.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

Patient Care Editorial Staff
December 20th 2024
Article

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

Smartphone App Shows Promise for Managing Hypertension in Observational Study / Image credit: ©ra2 studio/AdobeStock

Smartphone App Shows Promise for Managing Hypertension in Observational Study

Sydney Jennings
December 20th 2024
Article

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

© 2024 MJH Life Sciences

All rights reserved.